Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis

Shangyu Chai¹, Ruya Zhang¹, Ye Zhang¹, Richard David Carr², Yiman Zheng¹, Swapnil Rajpathak³ and Linong Ji⁴*

¹Merck Research Laboratories (MRL) Global Medical Affairs, Merck Sharp & Dohme (MSD) China, Shanghai, China, ²Hatter Cardiovascular Institute, University College London, UK and Ulster University, Coleraine, United Kingdom, ³Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, United States, ⁴Department of Endocrinology, People’s Hospital of Peking University, Beijing, China

Aims: Hyperglucagonemia occurs in the pathogenesis of type 2 diabetes mellitus (T2DM). In this meta-analysis, we summarized the effects of DPP4 inhibitors on glucagon levels in patients with T2DM.

Materials and methods: Randomized controlled trials (RCTs) comparing the influence of DPP4 inhibitors on circulating glucagon levels with placebo or other oral antidiabetic drugs (OADs) in patients with T2DM were identified by searches of Medline (PubMed), Embase (Ovid), and CENTER (Cochrane Library). Only studies reporting changes in glucagon level presented as total area under the curve (AUCglucagon) using a meal or oral glucose tolerance test were included. Results were combined using a random-effects model that incorporated potential heterogeneity among the included studies.

Results: A total of 36 RCTs with moderate to high quality were included. Overall, the numbers of T2DM patients included for the meta-analyses comparing DPP4 inhibitors with placebo and other OADs were 4266 and 1652, respectively. Compared to placebo, DPP4 inhibitors significantly reduced circulating glucagon levels (standard mean difference [SMD]: -0.32, 95% CI: -0.40 to -0.24, P<0.001; I² = 28%). Analysis of subgroups revealed that study characteristics had no significant effect on results, such as study design (parallel group or crossover), number of patients, mean patient age, proportion of men, baseline HbA1c, duration of diabetes, background therapy, treatment duration, or methods for glucagon measurement (all P for subgroup differences >0.05). Moreover, DPP4 inhibitors significantly reduced glucagon levels compared to other OADs (SMD: -0.35, 95% CI: -0.53 to -0.16, P<0.001; I² = 66%), and the reduction in glucagon was greater in comparison with insulin.
secretagogues than in comparison with non-insulin secretagogues ($P$ for subgroup difference = 0.03).

**Systematic review registration:** [https://inplasy.com/](https://inplasy.com/), identifier INPLASY202280104.

**Conclusions:** DPP4 inhibitors are effective at reducing the circulating postprandial glucagon level in T2DM patients.

**KEYWORDS**
dipeptidyl peptidase-4 inhibitor, glucagon, hyperglucagonemia, randomized controlled trials, meta-analysis

**Introduction**

Currently, type 2 diabetes mellitus (T2DM) is one of the key factors contributing to morbidity and mortality worldwide (1, 1). It has conventionally been believed that insulin resistance and impaired insulin secretion are the key mechanisms underlying T2DM development (2, 3). Despite this common knowledge, abnormally elevated serum levels of glucagon (hyperglucagonemia) also contribute to diabetes pathogenesis (4–6), which may reflect $\alpha$-cell dysfunction within the pancreatic islets. Clinical discussions often focus on insulin, but glucagon has an equally important role to play in understanding T2DM (7). Actually, all types of poorly controlled diabetes are associated with hyperglucagonemia (8). Therefore, treatment targeting hyperglucagonemia may also become an established antidiabetic strategy (9). There are several potential mechanisms for hyperglucagonemia in T2DM, including $\beta$-cell dysfunction, disturbances in $\alpha$-cell/$\beta$-cell interplay, and dysfunctional incretin effect (10–13). Knowing the role of glucagon is crucial to appreciating differences in glucose-lowering therapies’ mechanisms of action. Amongst oral anti-diabetic drugs (OADs), dipeptidyl-peptidase 4 (DPP-4) inhibitors are a well-applied class of glucose-lowering medications that function by inhibiting the DPP-4–induced degradation of incretin hormone glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The benefits of DPP-4 inhibitors in T2DM are not only limited to their regulation of insulin secretion in a glucose-dependent manner, but also include their efficacies in attenuating $\beta$-cell loss and improving glycemic durability (14, 15). Moreover, through increasing endogenous levels of the incretin hormones (10, 16), DPP-4 inhibitors have been suggested to suppress endogenous glucagon production in T2DM.

Compared with insulin, our understanding, research and detection methods for glucagon are not so well established. To the best of our knowledge, no consensus or gold standard has been reached regarding the optimal methods for measuring the serum glucagon concentration. In spite of the fact that plasma glucagon levels are not used in clinical stratification of diabetes treatment, health care providers may gain clinical insight by understanding how to control plasma glucagon levels pharmacologically in T2DM patients. In patients with T2DM, glucagon levels typically rise during fasting and then fail to decrease appropriately or even rise during oral glucose tolerance testing (OGTT) or after ingestion of a carbohydrate-rich meal, leading to undesirably high plasma glucagon with hyperglycemia. Typically, the effects of antidiabetic treatment on the postprandial glucagon level are measured by the changes in glucagon total area under the curve (AUC$_{glucagon}$) using a meal tolerance test (MTT) or a standard OGTT (17–19). Although there have been few small-scale randomized controlled trials (RCTs) evaluating the effect of DPP-4 inhibitors on plasma glucagon levels in patients with type 2 diabetes (20–55), little is known about the summarized efficacy of DPP4 inhibitors on AUC compared to placebo. There are also other oral glucose-lowering drug classes that affect glucagon secretion (positively or negatively), including sulfonylureas and sodium-glucose cotransporter 2 inhibitors (SGLT2is). Therefore, the summarized efficacy of DPP4 inhibitors on AUC$_{glucagon}$ compared to other OADs also seems interesting. To the best of our knowledge, no systematic review and meta-analysis has been published to date regarding the influence of DPP4 inhibitors on AUC$_{glucagon}$ in patients with T2DM. Accordingly, the aim of this study was to examine systematically the influence of DPP4 inhibitors on AUC$_{glucagon}$ in T2DM patients by performing a meta-analysis of RCTs.

**Abbreviations:** CI, confidence interval; DPP-4, dipeptidyl-peptidase 4; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; MTT, meal tolerance test; OADs, oral anti-diabetic drugs; OGTT, oral glucose tolerance test; RCTs, randomized controlled trials; SGLT2is, sodium-glucose cotransporter 2 inhibitors; SMD, standard mean difference; T2DM, type 2 diabetes mellitus.
Methods

This study adhered to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) (56) and Cochrane Handbook (57) guidelines during its design and implementation. The protocol of the meta-analysis was registered at the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY, https://inplasy.com/) with the registration number of INPLASY202280104. The PRISMA 2020 Checklist has been provided in the Supplementary Material.

Search strategy

In order to search Medline (PubMed), Embase (Ovid), and CENTER (Cochrane Library), the following strategies were used: (1) “DPP4” OR “DPP-4” OR “dipeptidyl peptidase-4 inhibitors” OR “sitagliptin” OR “vildagliptin” OR “linagliptin” OR “saxagliptin” OR “alogliptin” OR “dutagliptin” OR “aemigliptin” OR “anagliptin” OR “tenegliptin” OR “trelagliptin” OR “omarigliptin” OR “gemigliptin” OR “etvogliptin”; (2) “α cell” OR “α-cell” OR “glucagon” OR “alpha cell” OR “islet” OR “hormone” OR “hormonal” OR “meal” OR “prandial” OR “postprandial” OR “Oral Glucose Tolerance Test” OR “OGTT”; and (3) “random” OR “randomized” OR “randomised” OR “randomly”. Only studies including human subjects were considered. As part of the final database search, references to related reviews and original articles were also searched. The final database search was carried out on August 25, 2022.

Study selection

We included studies that met the following criteria: (1) English-language articles with full-length content; (2) RCTs with parallel groups or crossovers; (3) Adults with T2DM were randomly assigned to DPP4 inhibitors or placebo groups, or other OADs, for treatment; and (4) reported the changes of randomised controlled trial sequences; or those without a measurement of AUC_glucagon during MTT or OGTT setting were also excluded.

Data collection and quality evaluation

Database searches, data collection, and quality assessment were carried out by two authors independently. Discussions with the corresponding author were conducted if disagreements occurred. We collected data of study information (first author, publication year, and study country), study design (blind or open-label, crossover or parallel group), patient information (number of patients, mean age, sex, baseline hemoglobin A1c [HbA1c], and T2DM duration), details of background antidiabetic treatments, drugs and doses of DPP4 inhibitors used, regimens of controls, treatment durations, and methods for circulating glucagon measurement. The Cochrane Risk of Bias Tool was used to determine the quality of the included RCTs (57) according to the following aspects: assigning random sequences; concealing allocations; blinding participants and personnel; blinding outcomes assessors; incomplete outcomes data; and selective outcome reporting.

Statistical analysis

The effects of DPP4 inhibitors on circulating glucagon levels compared to controls in T2DM patients were presented as a standard mean difference (SMD) with 95% confidence interval (CI) because the methods and durations for measuring AUC_glucagon varied among the included RCTs. Heterogeneity was assessed using Cochrane’s Q test (58). It was also calculated the I² statistic, and an I² >50% indicates significant heterogeneity. A random-effects model was used when calculating pooled analyses, since it incorporates potential heterogeneity and provides more generalized results (57). Analyses of sensitivity were conducted by excluding one study at a time from the meta-analysis to evaluate the effect of each study on the pooled results (57). Additionally, sensitivity analyses limited to studies with FDA-approved DPP4 inhibitors and dosages were also performed, including sitagliptin 100 mg once daily, saxagliptin 5 mg once daily, linagliptin 5 mg once daily, and alogliptin 25 mg once daily. Analysis of predefined subgroups was conducted to determine whether study characteristics could influence the results, including study characteristics such as study design (parallel group or crossover), number of patients, mean patient age, proportion of men, baseline HbA1c, duration of diabetes, background therapy, treatment duration, and methods for glucagon measurement. For continuous variables, medians were selected as cutoffs for defining of subgroups. For a meta-analysis comparing DPP4 inhibitors and other OADs, subgroup analyses were performed according to whether the OADs taken by controls were insulin secretagogues or non-insulin secretagogues. An evaluation of publication bias was conducted via visual inspection of funnel plots and Egger’s
regression asymmetry test (59). For studies including multiple dose groups of DPP4 inhibitors, the shared control groups were equally split and included as independent comparisons to overcome a unit-of-analysis error, according to the instruction of Cochrane’s Handbook (57). Differences for which \( P < 0.05 \) were considered statistically significant. Statistical analyses were conducted using the RevMan (Version 5.1; Cochrane, Oxford, UK) software.

### Results

#### Literature search

Figure 1 illustrates the process of searching databases and identifying studies. Briefly, database searches yielded 2492 articles, and 1834 were retrieved after the duplicate records were excluded. Thirteen hundred eighty-four articles were subsequently excluded based on titles and abstracts, primarily because they were unrelated to the goal of the meta-analysis. Then, 414 articles out of the 450 that received full-text reviews were further excluded for the reasons illustrated in Figure 1. Finally, 36 RCTs (20–55) were deemed to be eligible for the meta-analysis.

#### Study characteristics and data quality

An overview of the included studies can be found in Table 1. Overall, 23 studies compared DPP4 inhibitors with placebo (20–22, 25–27, 30–42, 44–47). Eight studies compared DPP4 inhibitors with other OADs (28, 48–55), and the other five studies included both comparisons with placebo and other OADs (23, 24, 28, 29, 43).

Accordingly, a total of 28 RCTs were available for the meta-analysis comparing the influence of DPP4 inhibitors with placebo on postprandial glucagon (20–47). The characteristics of these studies are presented in the upper panel of Table 1. Briefly, these studies were all RCTs including T2DM patients which were published between 2007 and 2018. Seven of them...
| Study | Country | Design | Patient number | Mean age | Male % | Baseline HbA1c % | T2DM duration years | Background treatment | Intervention | Control | Treatment duration days | Postprandial glucagon measuring |
|-------|---------|--------|----------------|----------|--------|-----------------|---------------------|---------------------|-------------|---------|--------------------------|-------------------------------|
| He 2007 | USA | R, DB, PC, CO | 12 | 53.5 | 46.2 | NR | 7.2 | Treatment naïve or with OAD | Vildagliptin 10mg, 25mg Bid | Placebo | 28 | MTT-4h, RIA |
| Vella 2007 | USA | R, DB, PC, CO | 14 | 53.1 | 35.7 | 6.1 | NR | Treatment naïve or with OAD (metformin etc.) | Vildagliptin 50mg Bid | Placebo | 10 | MTT-5h, RIA |
| Defronzo 2009 | USA | R, DB, PC | 401 | 54.6 | 50.1 | 8 | 6.5 | Metformin | Saxagliptin 2.5mg, 5mg Qd | Placebo | 147 | OGTT-3h, RIA |
| Ahren 2009 | Sweden | R, DB, PC, CO | 25 | 65.5 | 88 | 6.3 | 5.6 | Treatment naïve | Vildagliptin 50mg Bid | Placebo | 28 | MTT-2h, RIA |
| Rosenstock 2009 | USA | R, DB, PC, CO | 201 | 53.6 | 52.5 | 7.9 | 2.6 | Treatment naïve | Saxagliptin 2.5mg, 5mg Qd | Placebo | 168 | OGTT-2h, RIA |
| Jadzinsky 2009 | Argentina | R, DB, PC | 269 | 51.9 | 50.6 | 9.4 | 1.9 | Metformin | Saxagliptin 5mg Qd | Placebo | 168 | OGTT-3h, RIA |
| Kikuchi 2009 | Japan | R, DB, PC | 78 | 59 | 67 | 7.4 | 5.3 | Treatment naïve | Vildagliptin 10mg, 25mg, 50mg Bid | Placebo | 84 | MTT-2h, RIA |
| Hollander 2009 | USA | R, DB, PC | 384 | 54 | 49.5 | 8.3 | 5.2 | Thiazolidinedione | Saxagliptin 2.5mg, 5mg Qd | Placebo | 168 | OGTT-3h, RIA |
| Iwamoto 2010 | Japan | R, DB, PC | 129 | 59.7 | 62.3 | 7.6 | 5.5 | Treatment naïve | Sitagliptin 25mg, 50mg, 100mg Qd | Placebo | 84 | MTT-2h, RIA |
| Seino 2011a | Japan | R, DB, PC | 230 | 62.2 | 61.7 | 8 | 7.7 | Voglibose | Alogliptin 12.5mg, 25mg Qd | Placebo | 84 | MTT-2h, RIA |
| Seino 2011b | Japan | R, DB, PC | 318 | 58.9 | 73.1 | 7.9 | 6.6 | Treatment naïve | Alogliptin 6.25mg, 12.5mg, 25mg Qd | Placebo | 84 | MTT-2h, RIA |
| Henry 2011 | USA | R, DB, PC | 36 | 55.6 | 38.9 | 6.8 | 3.2 | Treatment naïve | Saxagliptin 5mg Qd | Placebo | 84 | OGTT-5h, RIA |
| Tremblay 2011 | Canada | R, DB, PC, CO | 36 | 58.1 | 83.3 | 6.8 | NR | Metformin | Sitagliptin 100mg Qd | Placebo | 42 | MTT-8h, RIA |
| Rauch 2012 | Germany | R, DB, PC | 80 | NR | NR | 7.3 | NR | Treatment naïve or with OAD | Linagliptin 5mg Qd | Placebo | 28 | MTT-2h, RIA |
| Eto 2012 | Japan | R, DB, PC | 99 | 57.2 | 84.8 | 8.3 | 6.8 | Treatment naïve | Teneligliptin 10mg, 20mg Qd | Placebo | 28 | MTT-2h, RIA |
| Bunck 2012 | The Netherlands | R, DB, PC | 59 | 57.2 | 59.3 | 6 | 1 | Treatment naïve | Vildagliptin 100mg Qd | Placebo | 350 | MTT-2h, RIA |
| Alba 2013 | USA | R, DB, PC | 94 | 54.9 | 57.1 | 7.9 | 2.4 | Treatment naïve or with OAD | Sitagliptin 100mg Qd | Placebo | 147 | MTT-3h, RIA |

(Continued)
### TABLE 1 Continued

**Comparisons between DPP4 inhibitors and placebo treatment**

| Study     | Country | Design                  | Patient number | Mean age (year) | Male % | Baseline HbA1c % | T2DM duration (years) | Background treatment | Intervention                  | Control  | Treatment duration days | Postprandial glucagon measuring |
|-----------|---------|-------------------------|----------------|----------------|--------|-----------------|-----------------------|----------------------|-------------------------------|----------|------------------------|---------------------------------|
| Kadowaki 2013 | Japan | R, DB, PC                | 324            | 58.2           | 65.7   | 7.8             | 6.2                   | Treatment naïve or with OAD | Teneligliptin 10mg, 20mg, 40 mg Qd | Placebo | 84                    | MTT-2h, RIA                       |
| Sjostrand 2014 | China | R, DB, PC                | 431            | 52.9           | 50.2   | 7.9             | 3.7                   | Metformin                    | Saxagliptin 5mg Qd            | Placebo | 168                   | MTT-3h, RIA                       |
| Van Raalte 2014 | The Netherlands | R, DB, PC | 49             | 58.9           | 71.4   | 6.7             | NR                    | Metformin and other OAD      | Alogliptin 20mg Qd            | Placebo | 112                   | MTT-8h, RIA                       |
| Vardarli 2014 | Germany | R, DB, PC, CO           | 20             | 59             | 80     | 7               | 5                     | Treatment naïve or with OAD  | Sitagliptin 100mg Qd           | Placebo | 5                     | OGTT-4h, RIA                       |
| Kadowaki 2014 | Japan | R, DB, PC                | 194            | 59.4           | 66     | 8.4             | 8.8                   | Glimepiride                  | Teneligliptin 20mg Qd         | Placebo | 84                    | MTT-2h, RIA                       |
| Hansen 2014 | Sweden | R, DB, PC                | 312            | 54             | 47     | 8.9             | 7.3                   | Dapagliflozin and metformin  | Saxagliptin 5mg Qd            | Placebo | 168                   | MTT-3h, RIA                       |
| Nishimura 2016 | Japan | R, OL                   | 38             | 63.4           | 72.5   | 7.7             | 7.6                   | Repaglinide                  | Sitagliptin 100mg Qd           | No treatment | 168                  | MTT-3h, RIA                       |
| Forst 2017 | Germany | R, DB, PC                | 44             | 63.8           | 90.9   | 8.1             | 9.7                   | Empagliflozin                | Linagliptin 5mg Qd            | Placebo | 28                    | MTT-3h, RIA                       |
| Ahn 2017 | Korea | R, DB, PC, CO           | 10             | 56.5           | 30     | 7.2             | 11.8                  | Treatment naïve or with OAD  | Gemigliflozin                  | Placebo | 28                    | MTT-4h, RIA                       |
| Fargnren 2018 | Sweden | R, DB, PC, CO           | 28             | 73.6           | 61     | 6.9             | 9.2                   | Metformin                    | Sitagliptin 100mg Qd           | Placebo | 28                    | MTT-2h, RIA                       |
| Dou 2018 | China | R, DB, PC                | 231            | 50.1           | 66.5   | 9.4             | 0.8                   | Metformin                    | Saxagliptin 5mg Qd            | Placebo | 168                   | MTT-3h, RIA                       |

### Comparisons between DPP4 inhibitors and other OADs

| Study     | Country | Design                  | Patient number | Mean age (year) | Male % | Baseline HbA1c % | T2DM duration (years) | Background treatment | Intervention                  | Control  | Treatment duration days | Postprandial glucagon measuring |
|-----------|---------|-------------------------|----------------|----------------|--------|-----------------|-----------------------|----------------------|-------------------------------|----------|------------------------|---------------------------------|
| Ahren 2010 | Sweden | R, DB                   | 259            | 57.5           | 53.4   | 7.3             | 5.7                   | Metformin                    | Vildagliptin 50mg Bid          | Glimepiride 6mg Qd (max)          | 657      | MTT-2h, RIA             |                                 |
| Seino 2011b | Japan | R, DB                   | 326            | 58.9           | 71.9   | 7.9             | 6.5                   | Treatment naïve             | Alogliptin 6.25mg, 12.5mg, 25mg Qd | Voglibose 0.2mg Tid            | 84       | MTT-2h, RIA             |                                 |
| Alba 2013 | USA     | R, DB                   | 95             | 53.4           | 51.4   | 8               | 2.4                   | Treatment naïve or with OAD  | Sitagliptin 100mg Qd          | Pioglitazone 30mg Qd            | 147      | MTT-3h, RIA             |                                 |
| Okada 2013 | Japan   | R, OL                   | 34             | 65.5           | 38.2   | 7.8             | 8.2                   | Treatment naïve or with OAD  | Sitagliptin 50mg Qd           | Miglitzone 50mg Tid            | 70       | MTT-2h, RIA             |                                 |
| Forst 2014 | Germany | R, OL                   | 39             | 64             | 69.2   | 7.4             | 7.8                   | Metformin                    | Linagliptin 5mg Qd            | Glimepiride 4mg Qd (max)         | 84       | MTT-5h, RIA             |                                 |
| Vardarli 2014 | Germany | R, DB, CO              | 20             | 59             | 80     | 7               | 5                     | Treatment naïve or with OAD  | Sitagliptin 100mg Qd           | Metformin 500mg Bid–Qid          | 5        | OGTT-4h, RIA            |                                 |

(Continued)
| Study   | Country | Design | Patient number | Mean age | Male % | Baseline HbA1c % | T2DM duration years | Background treatment | Intervention | Control | Treatment duration days | Postprandial glucagon measuring |
|---------|---------|--------|----------------|----------|--------|------------------|---------------------|---------------------|-------------|---------|------------------------|--------------------------------|
| Hansen 2014 | Sweden | R, DB  | 306            | 55       | 49     | 8.9              | 7.5                 | Metformin           | Saxagliptin 5mg Qd | Dasaglipitin 10mg Qd | 168     | MTT-3h, RIA            |
| Akiyama 2016 | Japan | R, OL, CO | 16            | 66       | 62.5   | 6.6              | 11.5                | Pioglitazone or metformin | Sitagliptin 50 and 100mg Qd each for a week | Mitiglinide 10mg Tid | 14      | OGTT-3h, RIA           |
| Xiao 2016 | China  | R, OL  | 41            | 68.9     | 56.1   | 7.2              | Newly diagnosed     | Metformin           | Sitagliptin 100mg Qd | Glimepiride 1-4mg Qd | 168     | OGTT-2h, ELISA         |
| Alsalm 2018 | Sweden | R, DB, CO | 28            | 63       | 71.4   | 6.8              | 5.8                 | Metformin           | Vildagliptin 50mg Bid | Dapagliflozin 10mg Qd | 14      | MTT-4h, RIA            |
| Dou 2018 | China  | R, DB  | 229           | 49.8     | 66.1   | 9.5              | 0.7                 | Treatment naive     | Saxagliptin 5mg Qd | Metformin 500-2000 mg per day | 168     | MTT-3h, RIA            |
| Scott 2018 | New Zealand | R, DB | 173            | 67.1     | 57.9   | 7.8              | 10.6                | Metformin           | Sitagliptin 100mg Qd | Dapagliflozin 5-10mg Qd | 168     | MTT-2h, RIA            |
| Nakagawa 2019 | Japan | R, OL  | 22            | 61.2     | 40.9   | 7                | 5.3                 | Treatment naive or with OAD | Anagliptin 100mg Bid | Metformin 500mg Bid | 28      | MTT-3h, LC-HRMS        |

DPP4, dipeptidyl-peptidase 4; HbA1c, glycosylated hemoglobin; T2DM, type 2 diabetes mellitus; R, randomized; DB, double blind; OL, open label; PC, placebo-controlled; CO, crossover; NR, not reported; OAD, oral antidiabetic drug; Bid, twice daily; Qd, once daily; Tid, three times daily; Qid, four times daily; MTT, meal tolerance test; OGTT, oral glucose tolerance test; RIA, radioimmunoassay; LC-HRMS, liquid chromatography-high resolution mass spectrometry.
were crossover studies (20, 24, 25, 27, 31, 37, 45), whilst the remaining studies were parallel-group RCTs. The mean ages of the patients varied between 51 and 74 years. Various DPP4 inhibitors were used among these studies, such as vildagliptin, saxagliptin, linagliptin, sitagliptin, alogliptin, teneligliptin, and gemigliptin, whilst placebo was used as the control in all of the included RCTs except one study which received no treatment (42). The treatment durations varied between 5 and 350 days, and circulating postprandial glucagon was measured with radioimmunoassay in MTT/OGTT settings. Using Cochrane’s Risk of Bias Tool, Table 2 provides a detailed analysis of the included RCTs.

A total of 13 studies compared circulating glucagon levels in T2DM patients treated with a DPP4 inhibitor or other OAD (23, 24, 28, 29, 43, 48–55). Vildagliptin, sitagliptin, linagliptin, saxagliptin, alogliptin, and anagliptin were used as treatments, while glimepiride, voglibose, pioglitazone, dapaglitazin, miglitol and metformin were used as controls. The mean ages of the patients varied between 51 and 69 years. The follow-up durations varied from 5–657 days. Circulating glucagon levels were measured by radioimmunoassay (23, 24, 28, 29, 43, 48–51, 53, 54), enzyme-linked immunosorbent assay (ELISA) (55), or liquid chromatography-high resolution mass spectrometry (52) in a MTT/OGTT setting. A detailed risk of bias assessment of the included RCTs can also be found in Table 2.

Comparisons between DPP4 inhibitors and placebo on circulating postprandial glucagon

Because 10 studies reported data according to multiple dosages of DPP4 inhibitors separately (20–23, 26, 30, 35, 38,

| Study       | Random sequence generation | Allocation concealment | Blinding of participants | Blinding of outcome assessment | Incomplete outcome data addressed | Selective reporting | Other sources of bias |
|-------------|-----------------------------|------------------------|--------------------------|---------------------------------|----------------------------------|---------------------|-----------------------|
| He 2007     | Unclear                     | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Vella 2007  | Unclear                     | Low                    | Low                      | Low                             | Low                              | Low                 | Low                   |
| Defronno 2009 | Unclear                  | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Ahren 2009  | Unclear                     | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Rosenstock 2009 | Unclear                | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Jadocky 2009 | Unclear                    | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Kikuchi 2009 | Unclear                    | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Hollander 2009 | Unclear                  | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Iwamoto 2010 | Unclear                    | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Seino 2011a | Low                        | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Seino 2011b | Unclear                     | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Henry 2011  | Unclear                     | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Tremblay 2011 | Unclear                  | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Rauch 2012  | Unclear                     | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Eto 2012    | Unclear                     | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Bunck 2012  | Unclear                     | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Alba 2013   | Unclear                     | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |
| Kadowaki 2013 | Unclear                   | Unclear                | Low                      | Low                             | Low                              | Low                 | Low                   |

(Continued)
41, 46), these datasets were included into the meta-analysis independently. Accordingly, 42 datasets from 28 RCTs were available comparing the effects of DPP4 inhibitors and placebo on circulating glucagon levels in T2DM patients (20–47). Studies included in this review showed mild heterogeneity (P for Cochrane’s Q test = 0.05, I² = 28%). Pooled results showed that compared to placebo treatment, DPP4 inhibitors significantly reduced the circulating postprandial glucagon level in patients with T2DM (AUC_gluca gon: SMD = -0.32, 95% CI: -0.40 to -0.24, P < 0.001; Figure 2A). The results were not significantly affected
by excluding one dataset at a time during the sensitivity analysis (SMD: -0.31 to -0.34, all P < 0.05). Sensitivity analyses limited to studies with FDA-approved DPP4 inhibitors and dosages showed consistent results (SMD = -0.34, 95% CI: -0.47 to -0.22, all P < 0.001; Figure 2B). Subgroup analyses showed that the results were not significantly affected by study characteristics such as study design (parallel group or crossover), number of patients, mean patient age, proportion of men, baseline HbA1c, duration of diabetes, background therapy, treatment duration, or methods for glucagon measurement (all P for subgroup difference >0.05; Table 3).

 Comparisons between DPP4 inhibitors and other OADs on circulating postprandial glucagon

One study reported data according to multiple dosages of DPP4 inhibitors separately (23), and these three datasets were included in the meta-analysis independently. Overall, the pooled results of 15 datasets from 13 RCTs (23, 24, 28, 29, 43, 48–55) showed that compared with other OADs, DPP4 inhibitors significantly reduced the circulating glucagon level in patients with T2DM (AUCglucagon: SMD=-0.35, 95% CI: -0.53 to -0.17, all P < 0.001).
to -0.16, P<0.001; I^2 = 66%; Figure 3A). Sensitivity analysis by excluding one dataset at a time did not significantly change the results (SMD: -0.30 to -0.39, all P<0.05). Subgroup analyses showed that compared with either insulin secretagogues or non-insulin secretagogues, DPP4 inhibitors still significantly reduce glucagon levels in T2DM patients, and the reduction of glucagon was more remarkable compared with insulin secretagogues (SMD: -0.76, 95% CI: -1.21 to -0.31, P<0.001) than with non-insulin secretagogues (SMD: -0.22, 95% CI: -0.42 to -0.02, P=0.03; P for subgroup difference =0.03; Figure 3B).

**Publication bias**

The funnel plots for the meta-analyses comparing DPP4 inhibitors with placebo and other OADs were symmetrical, suggesting low-risk of publication biases (Figures 4A, B). Egger’s regression tests also suggested low risk of publication biases (P=0.167 and 0.156, respectively).

**Discussion**

Based on a pooled analysis of RCT results, this meta-analysis concluded that DPP4 inhibitors are effective at reducing postprandial glucagon levels in T2DM patients compared to placebo, as evidenced by a significantly reduced AUC glucagon in MTT/OGTT settings in patients allocated to the DPP4 inhibitor arm. Moreover, multiple sensitivity and subgroup analyses confirmed the stability of the findings, which were not significantly driven by any one of the included studies or significantly affected by predefined study characteristics, such as study design (parallel group or crossover), number of patients, mean patient age, proportion of men, baseline HbA1c, duration of diabetes, background therapy, treatment duration, or methods for glucagon measurement. In addition, the pooled results of 13 eligible RCTs showed that DPP4 inhibitors may also significantly reduce the circulating postprandial glucagon level in T2DM patients as compared to other OADs. Researchers have suggested that factors originating from nutrient stimulation of...
the digestive tract may play a key role in this process, namely, that postprandial glucagon production may be gut-derived, not originating from the pancreas (60, 61). Therefore, we divided other OADs into two groups for subgroup analysis. The results of this subgroup analysis showed that DPP4 inhibitors significantly reduced glucagon levels in T2DM patients compared to both the insulin and non-insulin secretagogues, separately, and the reduction in glucagon level was more noteworthy compared to that achieved with insulin secretagogues than with non-insulin secretagogues. Taken together, these results indicate that DPP4 inhibitors are effective at reducing postprandial glucagon levels in T2DM patients, which may be an additional mechanism underlying their benefits in patients with T2DM.

As far as we know, this is the first meta-analysis examining how DPP4 inhibitors affect circulating postprandial glucagon levels in people with T2DM. Unlike pharmacological studies in healthy volunteers with a single dose of the medication, we only included studies with T2DM patients who were treated for a stable period with DPP4 inhibitors, aiming to show that the possible glucagon-lowering efficacy of DPP4 inhibitors is clinically relevant. Because the relevant data on glucagon levels after fasting is limited and the circulating level of glucagon is variable according to feeding status, we chose AUCglucagon using standard MTT/OGTT as the measurement rather than plasma glucagon level at a certain time to comprehensively reflect the dynamic status of postprandial glucagon (62). Studies including patients with concurrent insulin, GLP-1RAs or pramlintide would be included in the future.

FIGURE 3
Forest plots for the meta-analysis comparing the effects of DPP4 inhibitors and other OADs on circulating glucagon levels in T2DM patients. (A) Forest plots for the overall meta-analysis; and (B) forest plots for the subgroup analyses according to the OADs given to controls.
FIGURE 4
Funnel plots for the meta-analysis evaluating the influences of DPP4 inhibitors on circulating glucagon in T2DM patients. (A) Funnel plots for the meta-analysis comparing the effects of DPP4 inhibitors and placebo; and (B) funnel plots for the meta-analysis comparing the effects of DPP4 inhibitors and other OADs.
injections were also excluded, because the imbalance of these treatments between groups may significantly affect the circulating glucagon levels (63, 64). These methodological considerations minimized the possible confounding effects of other clinical factors on the level of glucagon. The glucagon-suppressing effect of DPP4 inhibitors in T2DM patients observed in this meta-analysis could be explained by the pharmacological mechanisms of the drugs and confirmed that DPP4 inhibitors improve glycemic control at least partially via influencing glucagon levels. As part of its biological function, GLP-1 stimulates insulin secretion and inhibits glucagon action when secreted by the small intestine’s L-cells. By inhibiting the DPP-4–induced degradation of GLP-1, DPP4 inhibitors enhance the inhibitory effect of GLP-1 on glucagon, which may be more remarkable in a hyperglucagonemic state in T2DM patients (64). Interestingly, glucose-dependent insulinotropic polypeptide also increases glucagon secretion under hypoglycemic and euglycemic conditions, but not under hyperglycemic conditions (65–67). This specific mechanism is rarely reported for other OADs, which is also consistent with our findings that DPP4 inhibitors significantly reduced circulating postprandial glucagon levels in T2DM patients as compared to other OADs. In view of the importance of hyperglucagonemia in the pathogenesis of T2DM, the results of this study highlight the additional benefits of glucagon suppression by DPP4 inhibitors compared to other commonly used OADs. Interestingly, accumulating evidence from clinical studies has suggested that similar to DPP-4 inhibitors, GLP-1RAs substantially lower glucagon concentrations in both the fasting state and after a meal, thus reducing the hyperglucagonemia in patients with T2DM (68, 69). However, nearly all cardiovascular outcomes trials conducted with DPP4 inhibitors in T2DM patients so far have demonstrated a neutral effect on major adverse cardiovascular events (70, 71).

This meta-analysis has several strengths, including a rigorous literature review, strict inclusion and exclusion criteria, and robust results, comprehensive full-text review to include available related RCTs, and performance of multiple sensitivity analyses to confirm the stability and robustness of the findings. However, this study also has limitations. First, the optimal assessment method for circulating glucagon remains to be developed (72). Therefore, differences in the measurement methods for glucagon among the included studies may have contributed to the clinical heterogeneity of the meta-analysis, such as the different durations for MTT/OGTT and assays for plasma glucagon. In addition, the data used for this meta-analysis were study-level rather than individual patient-level. Subgroup analyses, therefore, should be interpreted cautiously. Large-scale RCTs or meta-analyses based on individual patient data may be considered to validate whether patient characteristics or concurrent medications may influence the potential glucagon-suppressing effect of DPP4 inhibitors. Besides, although hyperglucagonemia has been known to be involved in the pathogenesis and progression of T2DM, studies evaluating the significance of hyperglucagonemia in determination of glycemic control and prognosis in patients with T2DM are rare, at least partly because of the lack of standard methods for glucagon measuring in clinical practice. Future studies are also needed in this regard.

Overall, the results of this meta-analysis showed that DPP4 inhibitors are effective at reducing circulating postprandial glucagon levels in T2DM patients. In view of the importance of hyperglucagonemia in the pathogenesis of T2DM, these results highlight the additional effect of DPP4 inhibitors in patients with T2DM.

Conclusions

In conclusion, this meta-analysis revealed the effectiveness of DPP4 inhibitors for reducing circulating postprandial glucagon levels in T2DM patients in comparison with placebo or other OADs. The results confirmed that DPP4 inhibitors improve glycemic control, in part, by affecting glucagon levels.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Author contributions

SC, YZ, and RC conceived, designed, or planned the study; SC collected data and conducted research; RZ and LJ performed or supervised analyses; RZ, SR and YMZ interpreted the results; SC wrote the initial paper; All authors provided substantive suggestions for revision or critically reviewed subsequent iterations of the manuscript, reviewed and approved final version of the paper, and for all aspects of the work in ensuring that questions related to the accuracy.

Funding

This study received funding from MSD China. The funder had the following involvement in the study: study design, data collection and analysis, and preparation of the manuscript.
Acknowledgments

Jingya Chen of MSD China Holding Co., Ltd., Shanghai, China, assisted literature research of the manuscript. Administrative assistance was provided by Li Qi of MSD China Holding Co., Ltd., Shanghai, China. Medical writing and editorial assistance were provided by Medjaden, Inc. This assistance was funded by MSD China.

Conflict of interest

SC, RZ, YZ and YMZ are employees of MSD China. SR is an employee of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, US.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Jia W, Weng J, Zhu D, Ji L, Lu J, Zhou Z, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev (2019) 35:e3158. doi: 10.1002/dmrr.3158
2. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev (2018) 98:2133–223. doi: 10.1152/physrev.00063.2017
3. Taylor R, Al-Mribah A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol (2019) 7:726–36. doi: 10.1016/S2213-8587(19)30076-2
4. Moon JS, Won KC. Pancreatic alpha-cell dysfunction in type 2 diabetes: Old kids on the block. Diabetes Metab J (2015) 39:9–1. doi: 10.4093/dmj.2015.39.1.1
5. Gilon P. The role of alpha-cells in islet function and glucose homeostasis in health and type 2 diabetes. J Mol Biol (2010) 432:1567–94. doi: 10.1016/j.jmb.2010.01.004
6. Wever Albrechtsen NJ, Kuhre RE, Pedersen J, Knop FK, Holst JJ. The biology of glucagon and the consequences of hyperglucagonemia. biomark Med (2016) 10.1141-51. doi: 10.2217/bmm-2016-0090
7. Haedersdal S, Lund A, Knop FK, Vilsboll T. The role of glucagon in the pathophysiology and treatment of type 2 diabetes. Mayo Clin Proc (2018) 93:217–39. doi: 10.1016/j.mayocp.2017.12.003
8. Gusmain Y, Masson MH, Philippe J. Glucagon: the renewal of an old hormone in the pathophysiology of diabetes. J Diabetes (2013) 5:102–9. doi: 10.1111/jdi.12002
9. Grondahl MF, Keating DJ, Vilsboll T, Knop FK. Current therapies that modify glucagon secretion: What is the therapeutic effect of such modifications? Curr Diabetes Rep (2017) 17:128. doi: 10.1007/s11892-017-0967-x
10. Lund A, Vilsboll T, Bagger JI, Holst JJ, Knop FK. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab (2011) 300:E1038–46. doi: 10.1152/ajpendo.00665.2010
11. Unger RH, Aguilar-Parada E, Muller WA, Eisentrault AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest (1970) 49:837–48. doi: 10.1172/JCI106297
12. Muller WA, Falona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response Carbohydrate Protein Ingestion N Engl J Med (1970) 283:109–15. doi: 10.1056/NEJM197007162830301
13. Menge BA, Gruber L, Jorgensen SM, Deacon CF, Schmidt WE, Vedhuis JD, et al. Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes. Diabetes (2011) 60:2160–8. doi: 10.2337/db11-0251
14. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol (2020) 16:642–53. doi: 10.1038/s41574-020-0399-8
15. Chen K, Kang D, Yu M, Zhang R, Zhang Y, Chen G, et al. Direct head-to-head comparison of glycemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trials. Diabetes Obes Metab (2018) 20:1029–33. doi: 10.1111/dob.13147
16. Ahren B, Foley JE. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia (2016) 59:907–17. doi: 10.1007/s00125-016-3899-2
17. Miyachi A, Kobayashi M, Mieno E, Goto M, Furusawa K, Inagaki T, et al. Accurate analytical method for human plasma glucagon levels using liquid chromatography-high resolution mass spectrometry: comparison with commercially available immunoassays. Anal Bioanal Chem (2017) 409:5911–8. doi: 10.1007/s00216-017-0534-0
18. Rodriguez-Diaz R, Tamayo A, Mara M, Caicedo A. The local paracrine actions of the pancreatic alpha-cell. Diabetes (2020) 69:550–98. doi: 10.2337/db22-0002
19. Gromada J, Chabosseau P, Rutter GA. The alpha cell in diabetes mellitus. Nat Rev Endocrinol (2013) 9:694–704. doi: 10.1038/nrrev.endo.2013-0097
20. He YL, Serra D, Wang Y, Campstreni J, Riviere GJ, Deacon CF, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet (2007) 46:577–88. doi: 10.2165/00003088-200704070-00003
21. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin (2009) 25:2401–11. doi: 10.1185/0300799090378735
22. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin (2011) 27 Suppl 3:21–9. doi: 10.1185/03007995.2011.614936
23. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin (2011) 27:1781–92. doi: 10.1185/03007995.2011.599371
24. Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and “isoglycemic” intravenous glucose. Diabetes (2014) 63:663–74. doi: 10.2337/db13-0805
25. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes (2007) 56:1475–80. doi: 10.2337/db07-0136
26. DeFronzo RA, Hisu MN, Garber AJ, Luiz Gross J, Duan R, Ravichandran S, et al. The efficacy and safety of saxagliptin when added to

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.994944/full#supplementary-material
metformin therapy in patients with inadequately controlled type 2 diabetes with metformin add-on therapy. Diabetes Care (2009) 32:1649-55. doi: 10.2337/dc08-1994

38. Ahn CH, Kim EK, Min SH, Oh TJ, Cho YM. Effects of gemigliptin, a dipetidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes. Diabetes Obes Metab (2017) 19:487–62. doi: 10.1111/dom.12831

39. Alba M, Ahren B, Izuczek SE, Guan Y, Mallick M, Xu L, et al. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function. Diabetes Obes Metab (2013) 15:1101–10. doi: 10.1111/dom.12145

40. Doi J, Ma J, Liu J, Wang C, Johnson E, Yao H, et al. Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial. Diabetes Obes Metab (2018) 20:590–8. doi: 10.1111/dobm.13117

41. Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: A 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab (2012) 14:1040–6. doi: 10.1111/j.1463-1326.2012.01662.x

42. Farnigren J, Persson M, Ahren B. Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study. Diabetes Obes Metab (2018) 20:1911–20. doi: 10.1111/dobm.13316

43. Forst T, Falk A, Andersson G, Fischer A, Weber MM, Voswinckel S, et al. Effects on alpha- and beta-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study. Diabetes Obes Metab (2017) 19:489–95. doi: 10.1111/dom.12838

44. Henry RR, Smith SR, Schwartz SL, Muddalar SR, Deacon CF, Holst JJ, et al. Effects of saxagliptin on beta-cell stimulation and insulin secretion in patients with type 2 diabetes. Diabetes Obes Metab (2011) 13:850–8. doi: 10.1111/j.1463-1326.2011.01417.x

45. Jadzinsky M, Pfitzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes Obes Metab (2009) 11:611–22. doi: 10.1111/j.1463-1326.2009.01056.x

46. Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab (2013) 15:810–8. doi: 10.1111/dobm.12092

47. Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab (2014) 16:418–25. doi: 10.1111/dob.12235

48. Tremblay AJ, Lamarche B, Deacon CF, Weisnagl SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab (2011) 13:1366–73. doi: 10.1111/j.1463-1326.2011.01362.x

49. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract (2009) 81:233–40. doi: 10.1016/j.diabres.2008.10.006

50. Sjostrand M, Iqbal N, Lu J, Hirshberg B. Saxagliptin improves glycemic control by modulating postprandial glucagon and c-peptide levels in Chinese patients with type 2 diabetes. Diabetes Res Clin Pract (2014) 105:185–91. doi: 10.1016/j.diabres.2014.05.006

51. Rauch T, Graefe-Mody U, Deacon CF, Ring A, Woerle HJ, et al. Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus. Endocr J (2013) 60:913–22. doi: 10.1507/endocrj.e13-0019

52. Xiao X, Cui X, Zhang J, Han Z, Xiao Y, Chen N, et al. Effects of sitagliptin as initial therapy in newly diagnosed elderly type 2 diabetics. A randomized controlled study. Exp Ther Med (2016) 12:3002–8. doi: 10.3892/etm.2016.3729

53. Mohler D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ (2009) 339:b2535. doi: 10.1136/bmj.b2535

54. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. In: The Cochrane collaboration. London: Wiley Press, 2011. Available at: www.cochrane handbook.org.

55. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 315:629–34. doi: 10.1136/ bmj.315.7109.629

56. Knop FK, Vildobill T, Madsbad S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic iv. glucose infusion contributes to the reduced increment in effect in type 2 diabetes mellitus. Diabetologia (2007) 50:797–805. doi: 10.1007/s00125-006-0566-z

57. Mathiesen ES, Bagger JL, Bergmann NC, Lund A, Christensen MB, Vildobill T, et al. The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-a review. Int J Mol Sci (2019) 20:1749. doi: 10.3390/ijms20174902

58. Abbas G, Haq QMI, Hamaed A, Al-Sibani M, Hussain H. Glucagon and glucagon-like peptide-1 receptors: Promising therapeutic targets for an effective management of diabetes mellitus. Curr Pharm Clin (2020) 20:250–8. doi: 10.2174/138161282666620031143231
65. Christensen MB, Calanna S, Holst JJ, Vilboll T, Knop FK. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. J Clin Endocrinol Metab (2014) 99:E418–26. doi: 10.1210/jc.2013-3644

66. Christensen M, Calanna S, Sparre-Ulrich AH, Kristensen PL, Rosenkilde MM, Faber J, et al. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. Diabetes (2015) 64:72–8. doi: 10.2337/db14-0449

67. Christensen M, Vedtofte L, Holst JJ, Vilboll T, Knop FK. Glucose-dependent insulinotropic polypeptide: A bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes (2011) 60:3103–9. doi: 10.2337/db11-0979

68. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes (2004) 53:1187–94. doi: 10.2337/diabetes.53.5.1187

69. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattiz H, Olvera-Alvarez L, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet (2009) 373:473–81. doi: 10.1016/S0140-6736(08)61246-5

70. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA (2019) 321:69–79. doi: 10.1001/jama.2018.18269

71. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med (2015) 373:232–42. doi: 10.1056/NEJMoa1501352

72. Holst JJ, Weyer Albrechtsen NJ. Methods and guidelines for measurement of glucagon in plasma. Int J Mol Sci (2019) 20(21):5416. doi: 10.3390/ijms20215416